The present disclosure describes a method of coupling a first compound to a second compound, the method comprising: providing the first compound having a fluorosulfonate substituent; providing the second compound comprising an alkene; and reacting the first compound and the second compound in a reaction mixture, the reaction mixture including a catalyst having at least one group 10 atom, the reaction mixture under conditions effective to couple the first compound to the second compound.

The present disclosure describes a method of coupling a first compound to a second compound, the method comprising: providing the first compound having a fluorosulfonate substituent; providing the second compound comprising an alkene; and reacting the first compound and the second compound in a reaction mixture, the reaction mixture including a catalyst having at least one group 10 atom, the reaction mixture under conditions effective to couple the first compound to the second compound.

A compound is provided of Formula (I), wherein R.sup.1 represents a C.sub.3 to C.sub.20 hydrocarbon group derived from an alcohol of formula R.sup.1OH, from a formate of formula R.sup.1OCH═O, or a cinnamyl aldehyde of Formula (II) wherein a compound of Formula I is capable of releasing a compound, when oxidized, selected from the group consisting of a fragrant alcohol of formula R.sup.1OH, a fragrant formate ester of formula R.sup.1OCH=0 and aryl aldehyde of Formula (III), wherein R.sup.2 is, independently, hydrogen atom, hydroxyl group, optionally substituted C.sub.1-C.sub.6 alkyl group, C.sub.1-C.sub.6 alkoxy group, or -0(C=0)CH(CH3).sub.2 wherein any two of R.sup.2 may form an optionally substituted 5 or 6 membered ring. The compounds are useful for example as a precursor for the prolonged delivery or release of fragrant compounds such as fragrant alcohols, fragrant aldehydes or fragrant formates. ##STR00001##

A compound is provided of Formula (I), wherein R.sup.1 represents a C.sub.3 to C.sub.20 hydrocarbon group derived from an alcohol of formula R.sup.1OH, from a formate of formula R.sup.1OCH═O, or a cinnamyl aldehyde of Formula (II) wherein a compound of Formula I is capable of releasing a compound, when oxidized, selected from the group consisting of a fragrant alcohol of formula R.sup.1OH, a fragrant formate ester of formula R.sup.1OCH=0 and aryl aldehyde of Formula (III), wherein R.sup.2 is, independently, hydrogen atom, hydroxyl group, optionally substituted C.sub.1-C.sub.6 alkyl group, C.sub.1-C.sub.6 alkoxy group, or -0(C=0)CH(CH3).sub.2 wherein any two of R.sup.2 may form an optionally substituted 5 or 6 membered ring. The compounds are useful for example as a precursor for the prolonged delivery or release of fragrant compounds such as fragrant alcohols, fragrant aldehydes or fragrant formates. ##STR00001##

The present invention relates to a process for preparing arylpropenes, especially 1-methoxy-4-(1-propenyl)benzene (anethole), by means of thermolysis of the corresponding 1,1-diarylpropanes.

The present invention relates to a process for preparing arylpropenes, especially 1-methoxy-4-(1-propenyl)benzene (anethole), by means of thermolysis of the corresponding 1,1-diarylpropanes.

The present invention relates to compounds that modify low density lipoprotein receptor (LDLR) expression. The compounds have the structural formula I shown below:

##STR00001##

wherein m, R.sub.1, n, R.sub.2 and R.sub.3 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or disorders associated with elevated levels of low density lipoprotein cholesterol (LDL-C).

The present invention relates to compounds that modify low density lipoprotein receptor (LDLR) expression. The compounds have the structural formula I shown below:

##STR00001##

wherein m, R.sub.1, n, R.sub.2 and R.sub.3 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or disorders associated with elevated levels of low density lipoprotein cholesterol (LDL-C).

OLED materials having the formula: T-A(-S-B(-P-B)m-S-A)n-T where A are independently selected rod-shaped, rigid molecular core units, S are independently selected flexible spacer units, B are polymerisable crosslinking groups independently selected, P are spacer groups independently selected, T are independently selected end groups, m are independently selected from values of from 1 to 4, n is equal to I to 3.

OLED materials having the formula: T-A(-S-B(-P-B)m-S-A)n-T where A are independently selected rod-shaped, rigid molecular core units, S are independently selected flexible spacer units, B are polymerisable crosslinking groups independently selected, P are spacer groups independently selected, T are independently selected end groups, m are independently selected from values of from 1 to 4, n is equal to I to 3.